Board of Directors
Mike Boggs, Managing Partner, Revelation Partners
Mr. Boggs is a managing partner at Revelation Partners and Leerink Revelation Partners. Mr. Boggs has been involved in Revelation Partners alternative financing strategy for almost nine years, executing over $100 million in secondary and direct investments. Mr. Boggs has transacted with counter-parties ranging from venture funds such as CHL Medical that desired financing solutions to support a portfolio company, to companies such as Angioscore that required investment capital, to founders seeking liquidity.
Some of Mr. Boggs' past investments include: AngioScore (acquired by Spectranetics), CardioMems (acquired by St. Jude), ePocrates (acquired by Athenahealth), Estech (acquired by Atricure), Trivascular (acquired by Endologix), Surgiquest (acquired by Conmed) and TEI Biosciences (acquired by Integra Life Sciences).
Prior Leerink Revelation Partners, Mr. Boggs was a vice president at Saints Capital where he originated and valued investments in the healthcare and consumer related technology sectors. He also worked within the Healthcare Group at RBC Capital Markets where he executed over $1 billion in both private and public transactions.
Mr. Boggs is a board observer at Raindance Technologies, a previous Advisory Board member at Thomas Weisel Healthcare Venture Partners during its liquidation process and a previous board observer of Angioscore and Endoscopic Technologies (Estech).
Mr. Boggs received a bachelor of science degree in Business from the Haas School of Business at the University of California, Berkeley.
Ittai Harel, General Partner, Pitango Venture Capital
Mr. Harel is a veteran of the life sciences field. He has over twenty years of industry experience directing a broad range of responsibilities, from product development and marketing to executive management, in areas such as pharmaceuticals, drug delivery, medical devices, and diagnostics. Before joining Pitango, Mr. Harel headed up corporate development at Nektar Therapeutics (NASDAQ: NKTR) where he was responsible for strategic planning, in-licensing, and mergers and acquisitions. Prior to his work with Nektar, Mr. Harel served as executive vice president at IDGene Pharmaceuticals. During the previous eight years, Mr. Harel held various management positions in Israel and in the U.S. with IDEXX Laboratories (NASDAQ: IDXX).
Mr. Harel currently serves on the board of directors of Inotek Pharmaceuticals, LifeBond, EarlySense, Valeritas, and Vertos Medical, and serves as chairman of the board at LifeBond and EarlySense.
Mr. Harel holds a BS in Chemical Engineering and Biotechnology from Ben Gurion University and an MBA from the MIT Sloan School of Management.
Daniel Pelak, Senior Advisor, Welsh, Carson, Anderson & Stowe
Mr. Pelak has served as a Vertos Medical director since 2008. He is a senior advisor with Welsh, Carson, Anderson & Stowe (WCAS), focusing on investments in the healthcare industry. Prior to joining WCAS, Mr. Pelak was the chief executive officer at InnerPulse, a privately held, early-stage cardiac medical device company. Prior to joining InnerPulse, he was the CEO of Closure Medical Corporation, a publically traded biomaterial-based medical adhesive company, until its acquisition by Johnson & Johnson in 2005. Mr. Pelak began his industry career at Medtronic, where he spent over 20 years. His executive assignments at Medtronic included vice president of U.S. Marketing, and worldwide responsibility for three different operating divisions as vice president and general manager.
Mr. Pelak's current or recent board positions are InnerPulse, Inc., and AGA Medical Corp., Affinergy, Inc., Mardil, Inc., Oncoscope, Inc. Mr. Pelak is a graduate of Penn State University with a BS in Biology.
John F. Ryan, Partner, ONSET Ventures
Mr. Ryan has served as a director of Vertos Medical since 2009. He joined ONSET Ventures in 2008 after focusing throughout his career on the founding, building and financing of companies across many sectors of the healthcare industry, at stages ranging from early company formation to large industry leaders.
Prior to ONSET, Mr. Ryan led the venture-investing efforts in the medical device sector for Panorama Capital, JPMorgan Partners, and Chase Capital Partners. During that time he led investments in and served on the board of directors of companies such as CardioKinetix, FlowCardia, Novasys Medical, and PowerVision. Previously Mr. Ryan worked with Morgan Stanley Venture Partners where he participated in investments in companies such as Intuitive Surgical (NASDAQ: ISRG), R2 Technologies (acquired by Hologic), and Rita Medical Systems (acquired by AngioDynamics). Mr. Ryan has also worked with Morgan Stanley's investment banking group as part of a team that was a global leader in M&A and business financing for healthcare companies.
At ONSET Ventures, Mr. Ryan focuses on helping to create or invest in companies in the medical technology and healthcare IT sectors. Mr. Ryan serves as a board member or board observer for Novasys Medical, Valeritas, and Vertos Medical.
Mr. Ryan holds an MBA from Harvard Business School as well as a bachelor of science degree with high honors from the University of Colorado. Mr. Ryan also serves on the board of directors of Mills-Peninsula Health Services hospital organization and on the medical device screening committee for the Life Science Angels investment group.
Eric Wichems, President & Chief Executive Officer, Vertos Medical
Mr. Wichems joined Vertos Medical in September 2011 and served as Vice President of Sales and Marketing prior to becoming president, chief executive officer and member of the board of directors. Previously, Mr. Wichems served as director of marketing for medical devices in the plastic surgery market for Allergan Medical. He has almost a decade of experience in the healthcare industry through product management, marketing, and strategic planning assignments at Allergan and Johnson & Johnson.
Mr. Wichems earned a bachelor degree in mechanical engineering from the University of Virginia, a master degree in engineering from North Carolina State University, and a MBA from Duke University.